Apieron Secures Series D Commitments

MENLO PARK, Calif., June 1 /PRNewswire/ -- In its Series D round of
fundraising, Apieron Inc. said that it closed on commitments from all of its
previous venture investors. The round presently includes Alliance Technology
Ventures, Canaan Partners, Draper Fisher Jervetson and Onset Ventures.

"With commitments from our previous venture investors, we are more than well
on our way to securing our financing target and closing the round," said Holly
McGarraugh, Apieron President and CEO. "The ongoing support of our past
investors is a significant vote of confidence in our plan to improve the
treatment of asthma with the simple, accurate, safe and efficient measurement
of exhaled nitric oxide, a well-documented marker for airway inflammation."

Apieron is a medical device company dedicated to developing innovative
solutions to improve the standard of care for people with asthma. Its
Insight(TM) eNO System measures exhaled nitric oxide (eNO) which is a well
established indicator of airway inflammation for asthma management. Utilizing
a proprietary biosensor, Apieron's Insight eNO System can detect trace amounts
of nitric oxide in a patient's breath. It is highly accurate, non-invasive,
safe, easy to use, and provides results in less than a minute. Current methods
and techniques used to manage and treat asthma are costly, time-consuming and
cumbersome.

A much awaited breakthrough in medical technology, and designed for the
physician's office, the Insight eNO System is a practical and affordable
device for inflammatory airway measurement in asthma. The measurement of eNO
has also been shown to optimize medication therapy and improve compliance
among patients with asthma.

Since closing its C round in 2007, Apieron received FDA clearance for its
Insight eNO System in March 2008 and began selling to physicians offices in
the United States. Apieron has also secured FDA clearance for a multi-use
sensor, which improves clinical practice flow by providing up to 10 tests on a
single sensor, virtually eliminating the warm-up time between patient tests.
The funds in the Series D round are to be used for market growth and
additional product development.

It is estimated that more than 26 million people in the U.S. suffer from
asthma, making it one of the most common and costly of all diseases. In fact,
every day in America 40,000 people miss school or work due to asthma and 5,000
people go to the emergency room due to an asthma attack. One-quarter of all
emergency room visits are asthma related and asthma is the most common chronic
childhood disease.

About the Insight eNO System

The Insight eNO System has been available for use in the physician's office
since March 2008. The system uses a proprietary biosensor technology to
measure exhaled nitric oxide, a well established indicator of asthma severity
and steroid responsive airway inflammation. Measuring eNO and determining the
level of airway inflammation can help clinicians more closely manage their
patients' inflammatory condition and therefore more precisely titrate
medications, which can lead to fewer asthma exacerbations.

About Apieron Inc.

Apieron Inc. is a private, venture-backed medical device company based in
Menlo Park, CA that was formed in early 2001 to develop a simple-to-use,
non-invasive monitor for the measurement of exhaled nitric oxide (eNO) for the
management of asthma. The Apieron biosensor technology platform utilizes a
patented technology that allows for the highly sensitive detection of selected
analytes like eNO. Apieron is committed to collaborating with physicians and
patients to develop innovative medical solutions to improve quality of life
and standards of care.

SOURCE Apieron Inc.

Steve DiMattia, +1-646-201-5445